Pre-clinical testing of S. typhimurium in a murine model provided evidence that the bacteria was able to interfere with inhibitory receptor PD-1, enhance tumor regression, and prolong the survival rate of tumor-bearing mice [227,228]. Here, PDCD1 is linked to neoplasm.